公开(公告)号：US20250034755A1

公开(公告)日：2025-01-30

申请号：US18915899

申请日：2024-10-15

Applicant: CytomX Therapeutics, Inc.

Inventor： Sherry Lynn La Porte ,  Stephen James Moore ,  James William West

IPC: C40B30/06 ,  C07K14/00 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C12N15/10 ,  C12Q1/37 ,  C40B40/02 ,  G01N33/68

Abstract: The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics.

公开(公告)号：US20240228603A1

公开(公告)日：2024-07-11

申请号：US18400894

申请日：2023-12-29

Applicant: CytomX Therapeutics, Inc.

Inventor： Nancy Elizabeth STAGLIANO ,  James William WEST ,  Kathryn KAMATH ,  Paul Henry BESSETTE ,  Fred GLUCK ,  Jason Gary SAGERT ,  Patrick DAUGHERTY

IPC: C07K16/22 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  G01N33/68

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K47/6845 ,  A61K47/6849 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K16/00 ,  C07K16/18 ,  C07K16/241 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/2845 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/30 ,  G01N33/6845 ,  G01N33/6854 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50

Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.

公开(公告)号：US20240084010A1

公开(公告)日：2024-03-14

申请号：US18472748

申请日：2023-09-22

Applicant: CytomX Therapeutics, Inc.

Inventor： Bryan Allen IRVING ,  Sherry Lynn LA PORTE ,  Jason Gary SAGERT ,  Daniel Robert HOSTETTER ,  Olivia Jennifer RAZO ,  Clayton William WHITE ,  Jennifer Hope RICHARDSON

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  C07K16/30

CPC classification number: C07K16/2809 ,  A61K39/395 ,  A61K47/6803 ,  A61K47/6831 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6879 ,  A61K47/6889 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/92

Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US11884746B2

公开(公告)日：2024-01-30

申请号：US17240278

申请日：2021-04-26

Applicant: CytomX Therapeutics, Inc.

Inventor： Stephen James Moore ,  Margaret Thy Luu Nguyen ,  Daniel Robert Hostetter ,  Olga Vasiljeva

IPC: C07K7/06 ,  A61K47/65 ,  A61K47/68 ,  C07K7/08 ,  C07K16/00 ,  A61K49/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K7/06 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6835 ,  A61K47/6889 ,  A61K49/0056 ,  C07K7/08 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/50

Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US11859010B2

公开(公告)日：2024-01-02

申请号：US17930143

申请日：2022-09-07

Applicant: CytomX Therapeutics, Inc.

Inventor： Leila Marie Boustany ,  Sherry L. La Porte ,  Bryan A. Irving ,  Jeanne Grace Flandez

IPC: G01N31/00 ,  G01N33/53 ,  C07K16/40 ,  C07K16/28 ,  A61P35/00 ,  C12N15/62 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2863 ,  C12N15/62 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73

Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.

公开(公告)号：US20230035290A1

公开(公告)日：2023-02-02

申请号：US17699846

申请日：2022-03-21

Applicant: CytomX Therapeutics, Inc.

Inventor： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Jason G. Sagert

IPC: C07K14/56 ,  C07K14/00 ,  C07K14/555 ,  A61K47/64 ,  A61K47/65 ,  C07K19/00 ,  C07K14/565 ,  C07K14/57 ,  C07K16/00 ,  G01N33/68 ,  C07K14/705 ,  C12N15/10

Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.

公开(公告)号：US20220296692A1

公开(公告)日：2022-09-22

申请号：US17618658

申请日：2020-06-12

Applicant: CYTOMX THERAPEUTICS, INC.

Inventor： Rachel Humphrey ,  Matthias Will ,  Yifah Yaron

IPC: A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: The invention relates generally to use of a neoadjuvant combination therapy of an activatable anti-PDL1 antibody and an anti-CTLA-4 antibody for the treatment of cancer.

公开(公告)号：US20220162332A1

公开(公告)日：2022-05-26

申请号：US17471804

申请日：2021-09-10

Applicant: CytomX Therapeutics, Inc.

Inventor： Rachel Humphrey ,  Lori Carman ,  Matthias Will ,  Beiyao Zheng ,  Kathe Balinski

IPC: C07K16/28 ,  A61K47/65 ,  A61P35/00

Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US11161906B2

公开(公告)日：2021-11-02

申请号：US14340872

申请日：2014-07-25

Applicant: CytomX Therapeutics, Inc.

Inventor： Henry Bernard Lowman ,  James William West ,  Sherry Lynn La Porte ,  Bryan Allen Irving ,  Daniel Robert Hostetter ,  Chihunt Wong

IPC: C07K16/28

Abstract: The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US20210179713A1

公开(公告)日：2021-06-17

申请号：US16725587

申请日：2019-12-23

Applicant: CytomX Therapeutics, Inc.

Inventor： Kimberly Ann Tipton ,  James William West ,  Chanty Mariategue Chan

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/30

Abstract: The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.